Author Archives: Eric Djimeu

Eric Djimeu

Eric serves as the Evaluation Officer for the Support to Large-scale Combination Prevention Evaluation Studies project and as such is responsible for quality assurance services related to the proposals and studies, funded under this project, to evaluate combination prevention approaches to HIV/AIDS. In this role he coordinates the work of expert advisors and liaises with the funders and the research teams. Eric also assists the 3ie evaluation office in providing quality assurance for impact evaluations funded under our Open Window and Thematic Window grant programs.
Read more

Seven impact evaluations on demand creation for VMMC: how a focused thematic window can meet multiple evidence needs

World AIDS Day 2015
and | November 30, 2015

On World AIDS Day 2015, we are marking the culmination of 3ie’s third thematic window, which funded seven pilot programmes and rapid impact evaluations looking for ways to increase the demand for voluntary medical male circumcision (VMMC). In late 2013, we awarded grants to project teams of implementers and researchers to pilot innovative programs for
Read more…

Demand creation for voluntary medical male circumcision: how can we influence emotional choices?

World AIDS Day 2014
and | December 1, 2014

This year in anticipation of World AIDS Day, UNAIDS is focusing more attention on reducing new infections as opposed to treatment expansion. As explained by Center for Global Development’s Mead Over in his blog post, reducing new infections is crucial for easing the strain on government budgets for treatment as well as for eventually reaching
Read more…

Requiring fuel gauges: A pitch for justifying impact evaluation sample size assumptions

and | October 17, 2014

We expect researchers to defend their assumptions when they write papers or present at seminars. Well, we expect them to defend most of their assumptions. However, the assumptions behind their sample size, determined by their power calculations, are rarely discussed. Sample sizes and power calculations matter. Power calculations determine sample size requirements, which match budget
Read more…

Can we learn more from clinical trials than simply methods?

| August 16, 2013

What if scientists directly tested their drug ideas on humans without first demonstrating their potential efficacy in labs? This question sounds hypothetical because we all know that using untested drugs can be potentially dangerous. If we were then to use the same logic, should we not be exercising similar caution with randomized controlled trials (RCTs)
Read more…

Special feature for World AIDS Day 2012

Tackling HIV/AIDS: what works?
| November 30, 2012

There has been only a small decline in the prevalence of HIV in the last decade, dropping from 5.9 percent to 5 percent between 2001 and 2009 for those aged 15-49 (UNAIDS, 2010). This decrease, whilst important, does not seem impressive compared to over US$5 billion spent fighting AIDS in low and middle income countries
Read more…